13 results about "PHA polymerase" patented technology

Disclosed is a Taq DNA polymerase mutant. Compared to a wild-type Taq DNA polymerase, the Taq DNA polymerase mutant has a mutation at one or more of amino acid positions 116, 439, and 468, wherein the amino acid sequence of the wild-type Taq DNA polymerase is set forth in SEQ ID NO: 1. Compared to the wild-type Taq DNA polymerase, the Taq DNA polymerase mutant of the present invention has higher enzyme activity than the wild-type enzyme; both single-site mutants and multi-site mutants show improved tolerance to corn leaf supernatant, mouse serum, and / or heparin sodium, and thus can be used for direct rapid amplification of samples.

The invention relates to the field of bioengineering, in particular to a Taq enzyme mutant, a nucleic acid molecule and application of the Taq enzyme mutant and the nucleic acid molecule. The invention provides a mutant of Taq DNA (deoxyribonucleic acid) polymerase, which has one or more amino acid site mutations on the basis of wild Taq DNA polymerase: the 507th site, the 543th site, the 551th site, the 742th site and the 664th site, and the amino acid sequence of the wild Taq DNA polymerase is as shown in SEQ ID NO: 75. The invention provides a novel mutant DNA (deoxyribonucleic acid) polymerase. Compared with a wild type DNA polymerase, the novel mutant DNA polymerase has higher inhibition resistance or higher dUTP (deoxyuridine triphosphate) doping capacity.

Disclosed are DNA polymerases having increased 5′-3′ strand displacement activity and substantially reduced 5′-3′ exonuclease and endonuclease activity relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.

The present disclosure provides family A DNA polymerases having a strand displacement activity, the variants thereof, and the uses thereof. In one embodiment, the family A DNA polymerase variants exhibit an enhanced activity, salt tolerance, or lower no-template control signal compared to corresponding wild-type family A DNA polymerase.

The invention relates to a T7 RNA polymerase mutant with K1F promoter recognition activity and application of the T7 RNA polymerase mutant in construction of gene circuit logic gate design. The T7 RNA polymerase mutant provided by the invention has RNA polymerase activity based on a K1F promoter, can recognize the corresponding K1F promoter, and keeps orthogonality with a T7 RNAP promoter on the full-length division polymerase variant and on the division polymerase variant with proximity dependency. Compared with the existing K1F RNA polymerase, the K1F RNA polymerase has the advantages of high specificity, enhanced RNA transcriptional activity and the like, the performance is obviously improved, the requirements of current gene circuit multi-path orthogonal regulation and control are met, and an effective candidate enzyme tool is provided for RNA research and application.

The present application relates to the field of biotechnology, in particular to a PHA polymerase immobilization connecting peptide and a PHA polymerase immobilization method. The present application provides a connecting peptide for PHA polymerase immobilization, and optimizes the PHA polymerase immobilization connecting system. Experimental results show that, under the connecting peptide and the PHA polymerase immobilization connecting system, the correct expression of the functional protein can be ensured, and most of the catalytic activity is maintained.

Described herein are replicable RNA systems using modified RNA-dependent RNA polymerases having increased trans-amplification activity as compared to the corresponding unmodified polymerases and their use in methods of treating and preventing disease.

Disclosed herein is an engineered fusion enzyme composed of a prokaryotic phage RNA polymerase (T7 RNAP) and a viral capping enzyme (NP868R) for the generation of RNA transcripts containing a 5′ 7-methylguanylate cap.

A kind of recombinant KOD polymerase.A KOD polymerase mutant, a protein, as follows: for the amino acid residue in the 267, 326, 347, 349, 353, 375, 378, 379, 380, 385, 451, 452, 453, 454, 457, 461, 465, 470, 474, 477, 478, 479, 480, 482, 484, 485, 486, 493, 496, 497, 514, 574, 584, 605, 610, 630, 665, 666, 667, 674, 676, 680, 682, 698, 707, 718, 723 and 729 of KOD DNA polymerase GH78 amino acid sequence at least one of the 48 positions is modified, other amino acid sequences are unchanged, obtain the protein with DNA polymerase activity;Compared with KOD DNA polymerase GH78, the recombinant DNA polymerase shows stronger reaction rate, better catalytic efficiency, better affinity and other advantages in catalysis, improves the reaction rate of DNA polymerase in sequencing, increases reaction read length.

Labeled nucleotide analogs comprising at least one avidin protein, at least one dye-labeled compound, and at least one nucleotide compound are provided. The analogs are useful in various fluorescence-based analytical methods, including the analysis of highly multiplexed optical reactions in large numbers at high densities, such as single molecule real time nucleic acid sequencing reactions. The analogs are detectable with high sensitivity at desirable wavelengths. They contain structural components that modulate the interactions of the analogs with DNA polymerase, thus decreasing photodamage and improving the kinetic and other properties of the analogs in sequencing reactions. Also provided are nucleotide and dye-labeled compounds of the subject analogs, as well as intermediates useful in the preparation of the compounds and analogs. Compositions comprising the compounds, methods of synthesis of the intermediates, compounds, and analogs, and mutant DNA polymerases are also provided.

The present application relates to the field of microbiological technology, and particularly relates to a viscous polyhydroxyalkanoate, and its preparation and use. The viscous polyhydroxyalkanoate can be produced by fermenting a Pseudomonas strain containing a mutant of PHA polymerase PhaC61-3, and can be used for the preparation of biodegradable products.

Labeled nucleotide analogs comprising at least one avidin protein, at least one dye-labeled compound, and at least one nucleotide compound are provided. The analogs are useful in various fluorescence-based analytical methods, including the analysis of highly multiplexed optical reactions in large numbers at high densities, such as single molecule real time nucleic acid sequencing reactions. The analogs are detectable with high sensitivity at desirable wavelengths. They contain structural components that modulate the interactions of the analogs with DNA polymerase, thus decreasing photodamage and improving the kinetic and other properties of the analogs in sequencing reactions. Also provided are nucleotide and dye-labeled compounds of the subject analogs, as well as intermediates useful in the preparation of the compounds and analogs. Compositions comprising the compounds, methods of synthesis of the intermediates, compounds, and analogs, and mutant DNA polymerases are also provided.

Disclosed herein is an engineered fusion enzyme composed of a prokaryotic phage RNA polymerase (T7 RNAP) and a viral capping enzyme (NP868R) for the generation of RNA transcripts containing a 5' 7-methylguanylate cap.